Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Sjogren-Larsson Syndrome at the 2015 Society for Inherited Metabolic Disorders Annual Meeting

LEXINGTON, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on the potential of its lead product candidate, NS2, to treat Sjögren-Larsson Syndrome (SLS) has been accepted for a poster presentation at the upcoming 2015 Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held March 28-31, 2015 in Salt Lake City, Utah.

SLS is a rare disease caused by mutations in an aldehyde-metabolizing enzyme, fatty aldehyde dehydrogenase. In SLS, aldehyde-mediated modification of lipids (fats) is thought to disrupt the dermal moisture barrier, leading to the severe ichthyosis (dry, scaly, thickened skin) that is characteristic of the disease. Aldeyra will present the objectives, methods and results of preclinical studies evaluating the efficacy of an aldehyde trapping agent, NS2, in blocking aldehyde modification of phosphatidylethanolamine (PE), a critical lipid in biological membranes and the dermal moisture barrier. The data suggest that NS2 could have significant utility in treating the dermatologic manifestations of SLS.

The poster and date of the presentation is provided below.

  • Aldehyde Trapping Agent NS2 Blocks Formation of Fatty Aldehyde Adducts with Phosphatidylethanolamine and Suggests Potential Therapeutic Approach for Sjögren-Larsson Syndrome
    Poster: 79
    Date: Sunday, March 29, 2015
    Location: Imperial Ballroom at the Grand America Hotel, Salt Lake City, UT

Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, "We look forward to presenting this data that suggest the potential of NS2 to ameliorate the debilitating symptoms of SLS, a rare but serious life-long condition. We are optimistic about the activity of NS2 based on data generated to date, and believe the abstract acceptance is a testament to the importance of discovering a therapy for SLS, for which there are currently no FDA-approved drugs."

NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping free aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate aldehyde-mediated toxicity. As a product candidate, NS2 is currently being evaluated to address two underserved rare diseases, SLS and noninfectious anterior uveitis.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to initiate Phase II clinical studies of NS2 in Sjögren-Larsson Syndrome and noninfectious anterior uveitis in 2015. NS2 has not been approved for sale in the U.S. or elsewhere.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra's plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the potential markets for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency of Aldeyra's cash resources and needs for additional financing; Aldeyra's ability to attract or retain key personnel; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

CONTACT: Corporate Contact: Stephen Tulipano Aldeyra Therapeutics, Inc. Tel: +1 781-761-4904 Ext. 205 Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009 dburke@theruthgroup.comSource:Aldeyra Therapeutics